Sector News

Icon buys MediMedia Pharma Solutions for $120 million

February 2, 2015
Life sciences
Ireland-based Icon is to acquire MediMedia Pharma Solutions for $120 million, creating “the industry’s leading integrated scientific communications and market access solution”.
 
The Yardley, Pennsylvania-based company is a division of MediMedia USA and is being sold by Vestar Capital Partners. The deal includes MediMedia Managed Markets and Complete Healthcare Communications. The former provides “strategic payer-validated market access solutions”, while the latter is an agency which works with medical affairs, commercial and brand development teams within life science companies.
 
Icon chief executive Ciaran Murray said “the need to demonstrate and communicate the value of new medicines is an important global healthcare trend” and the acquisition of MediMedia Pharma Solutions “deepens the expertise” of the company’s existing operations “and brings us outstanding scientific and medical communications capabilities”.
 
The deal comes days after Icon announced plans to create 200 new jobs as part of a new global innovation hub in Ireland, with the posts split between Dublin and Limerick.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]